![]() |
Medicines
Management |
|
Features |
Putting some sense into brand-switching of diltiazem
Although, in many instances, prescribing generically is welcomed, the BNF recommends that modified-release longer-acting formulations of diltiazem be prescribed by brand because different preparations may not have the same clinical effect. In the "generic-craze" drugs such as diltiazem have inadvertently been switched from brand to generic. There are several different brands of diltiazem on the market 13 at the last count. Different pharmacies stock various brands of diltiazem and patients who "pharmacy-hop" may find that they receive a different brand of diltiazem each time they have their prescription dispensed. This prompted me to look into whether or not it was possible to assign a brand to diltiazem modified-release preparations when they were prescribed generically so that patients would continue to receive the same product wherever they took their prescription. Choosing the brand Before beginning this exercise I needed to choose a brand of diltiazem to switch patients to. I opted for Zemtard XL® as the brand of choice; it is a convenient once-daily formulation, and considerably cheaper than other alternatives. It is also one of the once-daily formulations recommended by Doncaster West Primary Care Trust in its "Drug Rationale and Evidence-Based Formulary". Searches on EMIS PCS/MicroDoc revealed that although some patients were on unbranded once-daily preparations, the most common prescriptions seen were for diltiazem m/r 60mg tablets, one three times daily and diltiazem m/r 90mg tablets, one twice daily. For patients on unbranded once-daily preparations, I was faced with the dilemma of either changing all prescriptions to Zemtard XL® or changing prescriptions to the brand patients were stabilised on. I decided to stick to the brand the patient was stabilised on in one practice (ascertained by liaising with local community pharmacists or contacting the patient) and change to Zemtard (XL®) for patients in another practice. For those patients on multiple doses of diltiazem, as well as complying with the clinical recommendation of prescribing by brand, I was able to apply strength alignment hence reducing the number of tablets/capsules the patient needed to take. Changes in letters Patients were informed of any changes to their regimen by letter and the three I used are reproduced here. As I expected, there were no concerns raised from patients whose prescription was amended to state the brand of diltiazem they were already receiving. To date, I have not had any queries from patients who have been changed from their once-daily formulation of diltiazem to Zemtard XL®. This is reassuring, and I am now switching all once-daily formulations to Zemtard XL® for patients in other practices.
Concerns about single doses I have had concerns raised from patients previously on multiple doses of diltiazem who have been changed to Zemtard XL®. Patients are concerned that taking, for example, 180mg of diltiazem as a single daily dose rather than 60mg three times daily will be "too much" for them. This came as a surprise to me as this has not been an issue when I have conducted strength alignment exercises in the past. However, with reassurance, and the option to revert back to the former dosing, most patients are willing to give Zemtard XL® a go. Having branded diltiazem products in most of the practices I work in, I am now awaiting PACT data for the relevant time period to see how successful this switch has been, and I will report on this for Medicines Management at a later date. |
|
|
Home | Journals | News | Notice-board | Search | Jobs Classifieds | Site
Map | Contact us
©The Pharmaceutical Journal